

Date: 06th May, 2021.

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Dear Sir,

Ref

: Script Id "BAJAJHCARE", Script Code "539872".

Sub

: Business Updates- Launch of Ivermectin Tablets (brand name "Ivejaj"), the commonly used Anti-Parasitic Drug now widely used in control & treatment for

Covid-19.

In terms of regulation 30 of SEBI (LODR) Regulations, 2015, please find attached herewith business updates - Launch of Ivermectin Tablets (brand name "Ivejaj"), the commonly used Anti-Parasitic Drug now widely used in control & treatment for Covid-19.

Kindly take the same on record.

Thanking you,

For and on behalf of Board of Directors of Bajaj Healthcare Limited

Aakash Kesari Company Secretary



## CIN: L99999MH1993PLC072892

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39A, B-39 A/1, Rd No.23, Wagle Ind. Estate Thane West, Maharashtra – 400604.

BHL launched Ivermectin Tablets (brand name "Ivejaj"), the commonly used Anti-Parasitic Drug now widely used in control & treatment for Covid-19.

**Thane, 6<sup>th</sup> May 2021**: Bajaj Healthcare Limited (BHL) a leading manufacturer of APIs, Intermediates and Formulations, has announced the launch of "Ivejaj" (Ivermectin) an Anti-Parasitic Drug now widely used in control & treatment for Covid-19 patients. BHL has received approval from India's drug regulator, to manufacture and market "Ivejaj" the oral Ivermectin approved medication in India for the treatment of COVID-19 from 6th May 2021.

**IVEJAJ Tablets** comprising Ivermectin. Ivermectin is an Anti-Parasitic Drugs, which is used to control parasitic roundworm infections and curing parasitic infections, helps to improve health of Covid-19 Patients. It works by paralyzing and killing parasites.

Commenting on the launch of "Ivejaj" (Ivermectin), Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said "We are pleased to add Ivermectin to our growing product portfolios. The second waves is more aggressive and bigger in number than the first. We hope the availability of an effective treatment such as Ivejaj will considerably ease the pressure and offer patients much needed and timely therapy option."

BHL has successfully developed the active pharmaceutical ingredient (API) and the formulation for Ivermectin through its own in-house R&D team. Most patients ailing from mild to moderate symptoms can benefit from the use of Ivejaj. The drug will be available as a prescription-based medication, with recommended doses.

The drug controller of India's has granted permissions to supply the "Ivejaj" (Ivermectin) in the domestic as well as in overseas market.

## **About Bajaj Healthcare Limited**

Bajaj Healthcare Limited a leading manufacturer of APIs, Intermediates and Formulations established in the year 1993. It specializes in manufacturing of of Amino Acids, Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, of which 6 units are dedicated to APIs, 2 units to Intermediates and 1 unit for formulation. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America.

## For further information on the Company, please visit www.bajajhealth.com

Rupesh Nikam (CFO) **Bajaj Healthcare Limited** 

Contact: +91 22 6617 7400

Email: <a href="mailto:investors@bajajhealth.com">investors@bajajhealth.com</a>

Krunal Shah/ Vinayak Shirodkar Captive IR Strategic Advisors Pvt. Ltd.

Contact: +91 22 4347 2247

Email: krunal@cap-ir.com / Vinayak@cap-ir.com

## Disclaimer:

CERTAIN STATEMENTS IN THIS DOCUMENT MAY BE FORWARD LOOKING STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES LIKE GOVERNMENT ACTIONS, LOCAL POLITICAL OR ECONOMIC DEVELOPMENTS, TECHNOLOGICAL RISKS, AND MANY OTHER FACTORS THAT COULD CAUSE OUR ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTEMPLATED BY THE RELEVANT FORWARD-LOOKING STATEMENTS. BAJAJ HEALTHCARE LTD WILL NOT BE IN ANY WAY RESPONSIBLE FOR ANY ACTION TAKEN BASED ON SUCH STATEMENTS AND UNDERTAKES NO OBLIGATION TO PUBLICLY UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT SUBSEQUENT EVENTS OR CIRCUMSTANCE